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1. Introduction 
Hepatitis C virus (HCV), an RNA virus classified within the Flaviviridae (12), has a 
remarkable propensity for persistence in the human host following acute infection. 
Infections spontaneously resolve in 20-30% of infected individuals, while 70-80% of 
infections result in long-term persistent viremia. Chronically infected individuals are at an 
increased risk of developing hepatocellular injury compared to subjects with acute resolved 
infections (25), with manifestations progressing from mild to severe (bridging) fibrosis, and, 
ultimately cirrhosis, in 10-30% of chronic infections.  Cirrhosis underlies life-threatening 
complications of end stage liver disease and/or hepatocellular carcinoma, after a long and 
extremely variable disease incubation period (25, 38).  It is presently impossible to predict 
which persons with chronic hepatitis C are at greatest risk for disease progression, and, 
likewise, host-virus relationships are most important for driving chronic hepatitis C  disease 
progression have not been defined.  In vitro evidence supporting the concept of virus-
mediated liver injury has recently been reported, including isolation of cytopathic 
derivatives of HCV infectious clone JFH1 (27), and also in the chimeric mouse (immune 
deficient mouse with humanized liver) hepatitis C model (18).  
Based on experimental data from acute liver injury rodent model systems, where massive 
hepatic necrosis is experimentally induced by toxins such as carbon tetrachloride (29), the 
master mediators of hepatic fibrogenic processes are Transforming Growth Factor beta 
(TGFbeta) and Platelet Derived Growth factor (PDGF) (17).  Hepatic Stellate Cells (HSCs) 
and macrophages appear to be the major cell types regulating hepatic fibrosis (17, 46).  
HSCs, normally quiescent in the liver, and potentially derived from hepatic oval cells (45), 
respond to injury by proliferation and secretion of large amounts of extracellular matrix 
proteins, in addition to pro-fibrogenic cytokines including TGFbeta.  During the process, 
HSCs are transformed into fibrogenic myofibroblasts.  A well characterized liver cirrhosis-
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associated antigen, Glial Fibrillary Acidic Protein (GFAP), is induced on pro-fibrotic cells 
such as HSCs, and is a definitive marker of fibrogenic pathway activation in this latter cell 
type (29).  Studies of fibrosis mechanisms in human liver are limited.   One longitudinal 
study, after liver transplantation, reported that increased density of GFAP in liver biopsy 
specimens predicted subsequent advanced fibrosis or cirrhosis (9).  Although cells harboring 
GFAP were only presumed to be activated HSCs, the study concluded that 30% of cells in 
cirrhotic livers may be activated HSCs.  However, the possibility of a direct effect of HCV on 
GFAP expression in hepatocytes was not investigated. 
The present study therefore examined the effect of HCV on hepatic fibrosis marker 
expression, using two human hepatoma cell line model systems, capable of supporting 
either non-productive HCV replication (HCV replicon, (22)), or productive HCV infection 
(genotype 2a infectious clone JFH1; (44)). The study also examined liver biopsy samples 
from HCV infected patients for the simultaneous presence of GFAP and HCV replicative 
intermediate RNA. Finally, microarrays were used to analyze expression of multiple cellular 
genes linked with liver fibrosis, in human hepatoma cell lines plus or minus HCV. The effect 
of HCV on differential expression of 153 genes (1, 3, 17, 28, 37) either involved in, or 
associated with, with the process of liver fibrosis, is reported.  
2. Methods 
2.1 Human liver biopsy specimens   
Thirty-two liver biopsy specimens, obtained under informed consent and per IRB-approved 
protocol, were available for study. All 32 subjects had chronic, active (viremic) HCV 
genotype 1 infections.  During procurement, the specimens were immediately preserved in 
OCT buffer and snap frozen at the bedside. Parallel sections of the liver biopsies were 
reviewed by a single pathologist who was blinded to HCV status and all other data.  Liver 
fibrosis severity, staged as 0 (no fibrosis) through 4 (cirrhosis), was assigned according to the 
system described by Batts and Ludwig (5).  For the present study, the liver specimens were 
de-identified for all information except HCV replication status and fibrosis severity. Fresh 
thin sections were obtained for the GFAP immunostaining experiments described below. 
Parallel sections of all 32 liver biopsy specimens were assayed for GFAP expression by 
immunocytochemistry.  29 of the specimens had been previously analyzed for both HCV 
genomic (G) and replicative intermediate (RI) RNAs by strand-specific in situ hybridization 
(ISH).  Details of the ISH assay, and assay results for a larger sample of hepatitis C cases, 
were previously reported (31).  Of 29 specimens with both GFAP and HCV replication data, 
HCV RNA was determined as either positive (G+RI+; 20 specimens), or negative (G-RI-; 9 
specimens), and GFAP staining level (% of cells per biopsy staining positive for GFAP, or 
%GFAP) was then analyzed as a function of HCV infection/replication status, and fibrosis 
stage.  
2.2 Hepatoma cell infection by JFH1 HCV 
  
Huh7.5.1 cells (48) were generously provided by Francis Chisari (Scripps Institute, La Jolla, 
CA).  Infection of Huh7.5.1 cells with the HCV JFH1 genotype 2a clone was performed as 
previously described (43), including the preparation of the JFH1 viral stock, cell infection, 
and titration.  Briefly, we inoculated naïve Huh7.5.1 cells with supernatant harvested from 
JFH1 RNA transfected cells. Naïve Huh7.5.1 cells were seeded 24 h before infection at a 
density of 1 x 106 per 10 cm dish. The cells were incubated with 2.5 ml of the JFH1 inoculum 
at an multiplicity of infection of 0.01 for 3 h, washed three times with PBS, and 
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supplemented with fresh complete Dulbecco's modified Eagle's medium.  Cells were 
collected 72 hours post infection and assayed for HCV infection and replication by western 
blot analysis, immunocytochemistry and/or real time PCR. 
2.3 Huh7-HCV replicon cells 
  
Huh7 cells containing either full-length genotype 1b HCV replicon, or a Huh 7.5 hepatoma 
subline with genotype 1a strain H77 replicon (FL-Neo replicon) (7), were obtained from C. 
Rice, Rockefeller Institute, and maintained in Dulbecco's modified Eagle's medium 
(Invitrogen) containing 400 µg/ml of G418 (Calbiochem; San Diego, CA) supplemented with 
10 % fetal calf serum (FCS) and 1 % penicillin/streptomycin at 37 °C in a 5 % CO2 atmosphere.  
2.4 Transfection of HCV genes  
Conditions for transient transfection of genotype 1a HCV core, NS3/4A, and NS5A genes 
cloned into expression vector pcDNA3.1 were previously described (30). The day prior to 
transfection, 0.5x106 Huh7.5.1 cells were plated overnight onto chamber slides. Endotoxin-
free plasmid DNA (0.5 µg) was purified (Endofree kit; QIAGEN, CA) and transfected with 
Lipofectamine 2000 according to the manufacturer's recommendations (Invitrogen, CA).  
2.5 Transfection of TGF beta siRNA  
100pmol of TGFbeta-specific siRNA was transfected in 0.5x106 cells 24 h after HCV gene 
transfection. Transfection of siRNA was carried out using Ambion si RNA transfection reagent 
kit (Ambion, TX) according to the manufacturer’s protocol.  Mock, non-targeting control 
siRNA, with limited sequence similarity to known genes (Silencer® Negative Control), was 
used as negative control (Ambion).  At 48 h post-transfection, total RNA and protein were 
harvested for immunoblot assay and real time RT-PCR, respectively.  For immunofluorescence 
assays, cells were grown in chamber slides for transfection, and fixed in 10% neutral buffered 
formalin at various times post-transfection, as indicated in the Results section. 
2.6 Antibodies and immunoblot analysis  
Protein concentrations in cell lysates were quantified (BCA Protein Assay; Pierce), and equal 
amounts of total protein (10-20 µg) were separated on 4 to 20% sodium dodecyl sulfate-
polyacrylamide electrophoresis (SDS-PAGE) gels. Immunoblot analysis was performed using 
a GFAP-specific monoclonal antibody (Dako, CA) followed by secondary antibodies 
conjugated to horseradish peroxidase (Jackson ImmunoResearch). The relative levels of GFAP 
protein were quantified in immunoblots using ImageQuant (version 5.1). The signals from the 
immunoblot were normalized against the signal from a common cellular housekeeping gene 
(GADPH), and the ratio of GFAP-specific signal to control GADPH signal was determined. 
2.7 Immunocytochemistry  
 Methods for immunocytochemistry (ICC) were as previously described (31, 32).  Briefly, 
snap frozen liver sections, or hepatoma cells from culture, were fixed in 10% neutral 
buffered formalin and subjected to immunohistochemistry.  Mouse monoclonal antibodies 
against GFAP were used at 1:100 dilution for 60 minutes (Affinity BioReagents, Co), 
followed by biotinylated goat antimouse immunoglobulins (dilution 1:200) for 30 minutes at 
room temperature. Samples were incubated with the Vectastain ABC alkaline phosphatase 
kit (Vector Laboratories, Burlingame, CA) for 30 minutes at room temperature to develop 
the vector red substrate. For double immmunostaining, anti-HCV core (Affinity 
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BioReagents, Co) anti-HCV NS3 (Vision Biosystem, MA) or anti-NS5A antibodies were used 
in combination staining, at 1:100 dilution for 60 minutes, followed by FIT-C conjugated goat 
antimouse immunoglobulins (dilution 1:200) for 30 minutes at room temperature. Mounting 
media containing DAPI (Vector laboratories, CA) was used to counter stain. 
2.8 RNA extraction   
Total cellular RNA was isolated from either HCV replicon, or negative control Huh7.5 cells, 
using 106 cells and an RNeasy miniprep Kit with an on column DNAse treatment following 
the manufacturer’s protocol (Qiagen). The RNA was quantified and quality checked using 
an Agilent Bioanalyzer platform (Agilent Technologies); using this standard, all RNA 
preparations were of highest quality and integrity. The RNA Integrity Numbers (RINs) of all 
the RNA samples were between 9.7 and 10.0. RINs greater than 6 represent RNA of 
sufficient quality for quantification experiments (13). 
2.9 Real-time RT-PCR  
Total RNA was extracted from uninfected or infected hepatoma cells, and reverse 
transcribed into cDNA using the superscript II first strand synthesis system according to the 
manufacturer’s protocol (Invitrogen, CA). Real-time quantitative PCR was carried out with 
an ABI 7900 Real-time PCR System, using the GAPDH gene as a reference (30). Three 
independent experiments were performed, and standard deviations calculated.  
2.10 Microarray Hybridization   
0.5µg of total RNA was used for a linear T7-based amplification step. To produce Cy3 
labeled cRNA, the RNA samples were amplified and labeled using the Agilent qucik Amp 
Labeling kit (Agilent Technologies). Yields of cRNA and dye incorporation rate were 
measured with a ND-1000 spectrophotometer (Nano-Drop Technologies).  Agilent whole 
Human genome Oligo Microarrays 4X44K (Miltenyi Biotech, Germany) were used to 
compare RNA samples from genotype 1a HCV replicon and Huh7.5 cells. The hybridization 
procedure was performed according to the Agilent 60-mer oligo microarray processing 
protocol using the Agilent Gene Expression hybridization kit (Agilent Technologies). 
Briefly, 1.65µg Cy3-labeled fragmented cRNA in hybridization buffer was hybridized 
overnight at 65°C. The microarrays were washed once with the Agilent Gene Expression 
Wash Buffer 1 for 1 min at room temperature followed by a second wash with preheated 
Agilent Gene Expression Wash Buffer 2 (37°C) for 1 min. The last washing step was 
performed with acetonitrile. Fluorescence signals of the hybridized Agilent Microarrays 
were detected using Agilent’s Microarray Scanner System (Agilent Technologies).  
2.11 Image and data analysis   
The Agilent Feature Extraction Software (FES) was used to process the microarray image 
files to determine feature intensities (including background subtraction) and reject outliers. 
All samples were labeled with Cy3. Rosetta Resolver gene expression data analysis system 
(Rosetta Biosoftware) was used to build pair-wise ratios and for data normalization.  
2.12 Statistical analyses   
In all experiments, including pixel count for GFAP fluorescence, densitometric scans of 
Western blots, RT-PCR analysis and GFAP antigen expression in liver biopsies by ICC, 
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results were calculated as the means (±S.D.) of three independent experiments.  For liver 
biopsy specimens, 3 different microscope fields were each read by 3 different trained study 
investigators, and results were averaged and compared using one-way analysis of variance. 
P values of 0.05 or less were considered statistically significant. 
3. Results 
3.1 Detection of GFAP and HCV RNA in parallel sections from HCV-infected human 
liver biopsies  
A previous study correlating intrahepatic HCV replication with liver fibrosis stage 
suggested a potential involvement of HCV in liver fibrogenesis [31]. Glial fibrillary acidic 
protein (GFAP) is a well-known marker of hepatic stellate cell (HSC) activation and liver 
cirrhosis.  Therefore, for the present study, GFAP expression was analyzed in parallel 
sections from ex vivo liver biopsy specimens obtained from 32 HCV genotype 1-infected 
research subjects.  All specimens had been scored previously for both liver fibrosis stage, 
while 29 specimens had been scored for HCV infection and replication status using viral 
RNA strand-specific in situ hybridization (ISH), as described previously (18). GFAP was 
determined by ICC and counting percentage of positive cells per biopsy. As expected, there 
was a significant correlation between percentage of liver cells staining positive for GFAP, 
and liver fibrosis stage (p<0.005) (Figure 1A).   20 specimens were positive for both HCV 
genomes and replicative intermediate RNAs (G+RI+), while 9 specimens were negative for 
both markers (G-RI-) despite chronic HCV infection confirmed by both enzyme 
immunoassay for HCV antibodies, and serum PCR for viral RNA.  Figure 1B demonstrates 
that GFAP staining was significantly increased in parallel sections from the HCV replication 
positive (G+RI+) liver biopsies, compared to the biopsies lacking HCV RNA signal (G-RI-) 
(mean 55% GFAP positive cells versus 16% GFAP positive, respectively; p<0.01).  
 
 
Fig. 1. Relationships between degree of liver fibrosis, GFAP expression, and genotype 1 
HCV infection and replication status, in parallel sections of 32 liver biopsy specimens from 
research subjects. Panel A: GFAP staining according to degree of liver fibrosis in parallel 
sections from 32 biopsies. Panel B: GFAP staining according to HCV replication status in 
parallel liver biopsy sections from 29 of the 32 subjects with chronic hepatitis C. * p<0.005; 
**p<0.01. 
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3.2 HCV induces GFAP expression in cultured human hepatoma cells 
To follow up these observations, a series of experiments examined the effect of HCV on 
cirrhosis antigen (GFAP) expression in well-characterized human hepatoma cell lines.  The 
HCV replicon efficiently replicates, but does not produce progeny virus, in hepatoma Huh 
7.5 cells (7, 22).  For this experiment, a gentotype 1b replicon was used.  Dual 
immunostaining of negative control Huh7.5 cells showed absence of the HCV core protein, 
and low or undetectable expression of the liver cirrhosis antigen, Glial Fibrillary Acidic 
protein (GFAP) (Figures 2A and B, respectively).  The presence of the HCV genotype 1b 
replicon, lead to significant induction of GFAP expression in Huh7.5 cells (Figures 2C and 
D, respectively).  These data were the first suggestion that GFAP expression was up 
regulated in human liver cells by HCV.  To confirm this result, and investigate if the results 
extend to more than one HCV genotype, GFAP expression was assayed in the human 
hepatoma cell line Huh7.5.1, in the presence, or absence, of the HCV genotype 2a infectious 
clone, JFH1 (44, 48).  Figures 2E and 1F show negative dual immunostaining of uninfected 
Huh7.5.1 cells for HCV core and GFAP, respectively, while increased staining of HCV core 
protein (Figure 2G) and GFAP (Figure 2H) were observed in the presence of JFH1 infection.  
Quantification of immunofluorescence signals (right hand panel of Figure 2) confirmed 
highly significant increases in GFAP antigen signal in hepatoma cells in the presence of 
either HCV replicon, or infectious clone JFH1, respectively (p<0.001 in both cases). 
 
 
Fig. 2.  Induction of GFAP in cultured human hepatoma cells. HCV core and GFAP signals 
were detected by dual label immunocytochemistry (ICC) using FITC and Texas Red channels, 
respectively. 40X magnification. In the bar graph, mean GFAP antibody fluorescence from 
triplicate experiments was quantified by metamorph and expressed as pixel count. ** indicates 
a significant increase in GFAP fluorescence in the presence of HCV, p < 0.001. 
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3.3 HCV core and NS5A genes both induce GFAP expression in hepatoma cells   
The HCV core gene encodes a virion structural component that is known to influence multiple 
cellular processes (25). Both NS3/4A (helicase and protease) and NS5A (kinase) genetic 
cassettes also encode cell regulatory functions (14, 23).  Thus, these three HCV genes (all 
derived from genotype 1b HCV) were each tested individually for induction of GFAP protein 
and RNA.  Huh7.5.1 cells were transfected with either empty, or HCV-protein-containing 
expression vectors, and dual-immunofluorescence was performed to detect GFAP, and the 
corresponding HCV antigens, 48 hrs after transfection (Figure 3). Figures 3A, B and C illustrate 
negative immunostaining for HCV core, GFAP and HCV NS5A antigens, respectively, 
following control vector transfection.  Transfection of the NS3/4A cassette also gave negative 
GFAP signal (data not shown).  However, GFAP signal was greatly enhanced in Huh7.5.1 cells 
transfected with either the HCV core gene (Figure 3E), or the NS5A gene (Figure 3F).  Figures 
3D and F confirm expression of the HCV core and NS5A proteins in transfected Huh7.5.1 cells, 
respectively. Interestingly, although HCV core expression was limited to a relatively small 
subset of transfected cells (Figure 3D), GFAP expression was widespread, and signal was 
strong even in cells that stained negative for HCV core antigen (compare green and red signals 
in Figures 3D and E).  This result suggested that a diffusible intermediate might be responsible 
for core-mediated GFAP induction in hepatoma cells.  In contrast, NS5A expression was more 
widespread throughout the transfected cells, the pattern of GFAP expression in response to the 
NS5A protein was more punctate and discrete than that observed following core transfection, 
and NS5A staining was observed in the same cells that showed increased GFAP expression 
(Figure 3F).  Quantitative assessment of GFAP immunofluorescence signals, summarized by 
bar graph in Figure 3, confirmed that the HCV core and NS5A proteins both significantly 
increased expression of GFAP in cultured hepatoma cells (p<0.001 in both cases).   
 
 
Fig. 3. HCV core and NS5A genes induce GFAP in hepatoma cell lines.HCV antigens and 
GFAP signals were detected using FITC and Texas Red channels, respectively. 40X 
magnification.  The bar graph compares GFAP signal intensity in the presence of vector or 
HCV gene products core, NS3/4A, or NS5A. 
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Experiments using cell extracts, summarized in Figure 4, were performed to confirm the 
results of cell surface staining.  To examine effect of HCV on GFAP protein expression 
within cells, total cell protein was harvested from Huh7.5 cells, HCV replicon-containing 
Huh7.5 cells, Huh7.5.1 cells infected with JFH1 virus for 72 hours, and Huh7.5.1 cells 
following transient transfection with individual HCV core, NS3/4A, or NS5A constructs.  
Protein extracts were subjected to Western Blot using the same panel of antibodies as used 
for Figures 2 and 3. GFAP expression was determined by quantification of GFAP pixel 
intensity in blot images, using GAPDH as control (Figure 4A).   
 
 
Fig. 4. Quantification of HCV effect on GFAP protein and RNA expression levels, by 
Western Blot (Panel A) and real time PCR (Panel B), respectively. Experiments were as 
summarized for Figures 2 and 3. Quantities of GFAP protein or RNA expression were 
averaged from three experiments. All data were normalized to GAPDH protein (Panel A) or 
RNA (Panel B) expression levels. * p < 0.05; **p<0.001. 
GFAP protein levels harvested from culture lysate were increased 1.8-fold in cells containing 
the HCV replicon, and approximately 1.7-fold in JFH1-infected cells relative to control cells.  
In cell transfection experiments using Huh7.5.1 cells as control, quantities of GFAP protein 
expression were increased by either the HCV NS5A gene (approximately 2.8-fold), or the 
HCV core gene (approximately 2.6-fold), while no significant effect on GFAP expression was 
observed following NS3/4A transfection.  The Western blot experiment confirmed that the 
genotype 1b HCV replicon, the genotype 2a HCV infectious clone JFH1, the HCV core gene 
product, and the NS5 gene product were all able to up regulate expression of GFAP protein 
in cultured hepatoma cells.  The effect of HCV on GFAP RNA expression in cultured 
hepatoma cells is presented in Figure 4B, under identical conditions to that described in 
Figure 4A.  GFAP RNA expression was increased in both HCV replicon cells (approximately 
3-fold), and JFH1-infected cells (approximately 6-fold), compared to cultured hepatoma cell 
line controls. Furthermore, Huh7.5.1 cells transfected with either the core construct, or the 
NS5A construct, showed approximately 3-fold increases in GFAP RNA expression, while no 
change in GFAP RNA expression was found following NS3/4A transfection (Figure 4B).  
3.4 TGFbeta mediates core induction of GFAP, but not NS5A induction of GFAP 
TGF-β is a known modulator of GFAP expression in human astrocytes (35), and the HCV 
core product is known to induce TGF-β expression in vitro (42).  Thus, we anticipated that 
HCV core induction of GFAP in hepatoma cells was TGF-β dependent.  As indicated in 
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Figure 5A, TGF-β RNA expression was increased approximately 3-fold in the presence of 
either JFH1 infection, or HCV core gene transfection, but not in the presence of either 
NS3/4A, or NS5A gene transfection.  RNA knockdown of TGF-β RNA, using TGF-β -
specific siRNA, blocked GFAP induction by the HCV core protein, but had no effect on 
GFAP induction by the NS5A protein (Figure 5B).  The data implicates a TGF-β dependent 
mechanism for induction of GFAP by the HCV core protein.  However, the data argue that 
the HCV NS5A gene product most likely induces GFAP expression by a TGF-β -
independent mechanism.  
 
 
(A)              (B) 
Fig. 5. Panel A: HCV induction of TGFbeta expression by real-time RT-PCR using cells 
transfected with either core, NS3/4A, or NS5A in pcDNA3.1 plasmids. Data were 
normalized to GAPDH RNA. *, p < 0.05; **, p < 0.001. Panel B: Differential effect of TGFbeta 
knockdown by siRNA on GFAP induction by HCV core and NS5A. (** Indicates p < 0.001). 
3.5 Extracellular matrix gene transcriptional responses induced in hepatoma cells by 
the HCV replicon   
To determine the breadth of effect of HCV on the extracellular matrix, microarray analysis 
was used to analyze, within hepatoma cells, the expression of 153 cellular genes associated 
with liver fibrosis (1, 3, 17, 28, 37), and to determine the effect of genotype 1a hepatitis C 
virus replication on matrix gene expression. Genes associated with cell-cell and cell-matrix 
interactions, along with those implicated in dysregulated tissue remodeling during repair 
and wound healing, were assessed in Huh7.5 cells in the presence or absence of the HCV 
replicon.  A change in gene expression was considered significant based on two criteria, a 
greater than 99% probability of being expressed differentially (P≤0.01), and a fold change of 
1.5 or greater, which is conservative. Figure 6 shows the log scatter plot of signal intensities 
of all spots representing expression levels of individual cellular genes in the presence (Y 
axis), or absence (X-axis), of the HCV replicon.  
The gene panel we analyzed included 20 collagen genes, and 133 non-collagen genes 
associated with the extracellular matrix (ECM) and cellular adhesion, including remodeling 
enzymes, cytokines, chemokines, growth factors, and genes involved in signal transduction.  
From the total of 133 non-collagen genes analyzed, 34 genes were induced by HCV, with 
induction values ranging from 1.5 fold to 100 fold (Figure 7 and Table I).  Another 30 genes 
were down regulated in the presence of HCV; again with a range of 1.5 fold to 100 fold 
(Figure 7 and Table I). Finally, 69 non-collagen genes showed no significant change in gene 
expression in the presence of HCV, relative to control cells (Table II).  
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Fig. 6. Pair-wise comparison of signal intensity on DNA microarrays hybridized with RNA 
from Replicon 1a (Fl-Neo) and Huh 7.5 -control cell lines. The red lines depict the p value 
cut off (p=0.01), while red and green crosses indicate up and down regulated genes in the 
Replicon 1a cell line relative to the control cell line.  
 
Fig. 7. Regulation of genes linked with hepatic fibrosis, by HCV. The red and green bar 
graph shows increased or decreased expression (relative to the control Huh 7.5 cells) of 
various cellular genes linked to liver fibrosis.  Expression level, on the vertical axis, refers to 
the Log-fold change in the transcript abundance of individual genes arranged on the 
horizontal axis. 
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Gene Characterization Gene Symbol Fold change P value 
Significantly up regulated in Replicon cells 
ECM and Cell adhesion 
MMP11 1.73 0.00025 
MMP14 1.54 0.00321 
MMP16 2.57 5 x10-10 
LOX 3.2 0.0 
LOXL1 7.4 0.00005 
   
PLG 68.079 8x10-6 
SERPINH1 2.9 5x10-10 
Remodeling Enzymes 
SERPINE2 8.0 4x10-18 
LAMB3 1.6 0.003 
LAMC1 1.7 0.0004 
ECM proteins 
LAMC2 4.5 3x10-14 
ITGA1  3.37 1x10-11 
ITGA2  2.46 9x10-7 
FBN1 3.8 1x10-12 
ECM1 1.8 0.007 
HAS1 8.0 0.00004 
CTNND2 5.37 3x10-16 
CLEC3B 2.022 0.00005 
VTN 2.12 1x10-6 
Cell Adhesion 
THBS4 32.0 3x10-22 
CAV1 1.5 2x10-21 
ENG (EVI1) 2.43 8x10-6 
INHBE 2.47 3x10-8 
THBS3 3.49 6x10-12 
TGFb super family 
TGIF1 1.62 0.001 
 NDRG4 18.7 3x10-21 
NFKB1 1.5 5x10-18 Transcription Factors 
NOTCH1 2.3 0.0 
Growth Factors IGFBP2 100 2x10-23 
 VEGFC 19.0 2x10-14 
CXCL6 5.5 1x10-9 
CXCL10 3.8 0.0004 
Cytokines 
GFAP 2.0 8x10-7 
Significantly down regulated in Replicon cells 
ECM and Cell adhesion 
PLAT 44.6 0.0 
PLAU 1.7 3x10-29 
SERPINE1  7.7 0.0 
TIMP1 100 3x10-23 
TIMP2 6.7 9x10-19 
Remodeling Enzymes 
TIMP4  2.8 1x10-9 
Table 1. Significantly dysregulated transcripts in Replicon Fl-Neo 
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Gene Characterization Gene Symbol Fold change P value 
Significantly down regulated in Replicon cells 
ECM and Cell adhesion    
ITGA3  13.2 1x10-10 
PECAM1 10.0 3x10-19 
Cell Adhesion Molecules 
FN1 2.4 2x10-8 
Extracellular matrix protein SPARC 4.3 8x10-14 
CTGF 4.8 8x10-15 
EDN1 2.1 0.0 
EGF 58.3 1x10-22 
Growth Factors 
PDGFA 1.67 0.0005 
CEBPB 1.9 0.0006 
JUN 3.4 0.0 
STAT6 9.2 7x10-19 
Myc 2.2 0.0 
Transcription Factors 
STAT 1 1.6 8x10-26 
CXCR4  2.4 3x10-5 
CCL3 4.2 0.0 
IL1B 3.7 1x10-45 
Inflammatory cytokines and 
chemokines 
SPP1 50.1 0.0 
TGFB1 3.4 0.0 
TGFB2 2.1 0.001 
TGFB3 11.7 2x10-19 
TGFb super family 
THBS1 1.6 0.0 
Cytoskeletal KRT19 11.0 1x10-19 
Kinase MST1R 1.8 0.0001 
Table 1. Significantly dysregulated transcripts in Replicon Fl-Neo (continuation) 
 
Pro-Fibrotic: 
ACTA2; SNAI1 
Basement Membrane: COL10A1 
FACITs : COL19A1, COL20A1 
Transmembrane: COL17A1 
Multiplexin Collagens: COL13A1, COL15A1, COL18A1 
ECM: LAMA1, LAMA2, LAMA3, LAMB1 
Remodelling Enzymes: MMP1, MMP2,MMP3, MMP9, MMP13, MMP14, ADAMTS1, 
ADAMTS8, ADAMTS13, SERPINA1 
Cellular Adhesion: ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, ITGB6, ITGB8, ITGAV, ITGA4, 
ITGA5, ITGA6, ITGA7, ITGAL. ITGAM, CDH1 
Inflammatory cytokines and chemokines: CCR2, CXCR4, CCL11, CCL2(MCP-1), IL-13, 
IL13RA2, IL4, IL5, IFNG, IL13RA2, IL1A, ILK, IL1RN 
Growth factors: AGT, PDGFB, VEGFA 
TGF beta super family: BMP7, DCN, GREM1, LTBP1, SMAD2, SMAD3, SMAD4, SMAD6, 
SMAD7, TGFBR1, TGFBR2, THSP2 
Transcription Factors: SP1, MITF 
Table 2. Transcripts with no significant change in gene expression 
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Gene Characterization Gene Symbol Fold Change P values 
Significantly up-regulated in Replicon cells 
COL2A1 100 2x10-23 
COL5A2 2.9 8x10-9 
Fibril forming  
COL11A1 2.8 1x10-9 
Non-Fibrillar  
COL4A2 2.2 4x10-7 
COL4A5 1.6 0.008 
COL4A6 1.9 0.00002 
Basement Membrane 
Collagen 
COL8A2 2.0 0.0006 
COL9A2 2.4 4x10-8 
COL9A3 10.0 3x10-19 
COL12A1 3.2 2x10-8 
COL14A1 53 6x10-18 
FACITs 
COL16A1 15.58 9x10-21 
Significantly down regulated in Replicon cells 
COL1A1 2.5 3x10-19 
COL1A2 4.6 0.0 
Fibril Forming  
Col3A1 3.8 1.3x10-9 
Non-Fibrillar 
Anchoring Filaments 
Collagen 
COL7A1 5.7 4x10-16 
Col6A1 5.9 3x10-16 Collagen of beaded 
microfilaments Col6A2 8.4 8.7x10-13 
Table 3. Significantly dysregulated Collagen transcripts in Replicon Fl-Neo 
The effect of HCV on expression of twenty known collagen genes is presented in Table III. 
These were grouped into two main molecular classes: the fibril forming species (collagens 
1,2,3,5), and non-fibrillar collagens (37). The non-fibrillar collagens were further subdivided. 
Nine collagen genes had increased transcript abundance in the HCV replicon positive cell 
line, while four collagen genes showed decreased transcript abundance in the presence of 
HCV. There was no significant change in the expression of remaining 7 collagen genes when 
compared to the control Huh 7.5 cells. We observed an increase in fibril forming collagen 
type 2 and 5. Col2A1 showed an increase of 100-fold. We also found an increase in 
expression of fibril forming, basement membrane and FACIT collagen molecules in the 
replicon cell line when compared to the huh7.0 cell line (Table III). However, of interest is 
the note that the expression of Col1A1 and Col1A2 was down regulated in the presence of 
HCV (Table I). Col3A1 was also down regulated in the presence of HCV.  
There was a 8-fold increase in hyaluronan synthase 1 (Has1) mRNA, along with an increase 
in transcript abundance of Integrins (ITGA1, ITGA2) and Laminin (LAMC1, LAMC2, 
LAMB3). Laminin is the main type of adhesive ECM component, and is associated with the 
basement membrane formation in liver during cirrhosis (Table I). 
The expression of fibrosis associated antigen, GFAP, was increased 2-fold in the presence of 
the genotype 1a HCV replicon, which is very similar to the value observed using real time 
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PCR analysis of GFAP RNA in the presence of the genotype 1b replicon (Figure 4B). The 
GFAP data, across multiple HCV genotypes, and different methods of analysis, argue for 
consistency of the observations of effect of HCV on cell matrix. TGFβ is a known modulator 
of GFAP in mature glial cells of the CNS, and the major mediator of fibrogenesis in Hepatic 
Stellate Cells. Surprisingly, TGFβ1, TGFβ2 and TGFβ3 were all down regulated in the 
presence of HCV replicon, compared to Huh7.5 controls. However, several of the other 
members of TGFβ super family (CAV1, ENG, INHBE, TGIF1, THBS3 and NDRG4) showed a 
significant increase in expression in the presence of HCV. 
4. Discussion 
Why fibrosis and cirrhosis are variable in chronic hepatitis C is unknown. The present study 
1) describes a significant relationship between HCV replication and cirrhosis antigen 
expression in vivo, 2) focused on the effect of 3 different HCV genotypes (1a, 1b and 2a) on 
expression of the liver cirrhosis-associated antigen Glial Fibrillary Acidic Protein (GFAP), 
and 3) also examined direct effects of hepatitis C virus on 153 cellular genes that contribute 
to the extracellular matrix (ECM).  The data indicate that HCV induces dramatic change in 
collagens, as well as some known mediators of fibrogenesis, including the cirrhosis antigens 
GFAP and Smooth Muscle Actin (data not shown).  Focus on GFAP revealed two distinct 
pathways: one TGFbeta dependent, and the other, TGFbeta independent, mediated by two 
different HCV proteins, core and NS5A.  Independent modulation of GFAP expression by 
two different HCV proteins, via different mechanisms, implies an important function.  Two 
possible implications of the results are:  1) That specific cell surface components play an 
important role the HCV life cycle; and 2) That HCV may directly accelerate fibrogenesis 
from within hepatocytes, since many of the molecules induced are profibrogenic in 
experimental models.  
The ECM is a complex molecular network that helps determine the specific architecture of a 
tissue. During hepatic fibrogenesis, major changes occur in both the quantity and quality of 
hepatic ECM (for review, see ref (37)). Increase in abundance of collagen molecules is the 
major hallmark of liver fibrosis (6). In the normal liver, the sub-endothelial space of Disse 
contains both an interstitial and a basement membrane-like ECM of low density. The 
perisinusoidal matrix is composed of fibrillar collagen types I, III, and V, microfibrillar 
collagen VI, basement membrane collagens IV and XVIII, traces of FACIT collagens XIV, 
and small proteoglycans decorin, fibronectin, tensacin-c, laminin and others (36). As the 
liver becomes fibrotic, significant qualitative and quantitative changes of the ECM occur, 
predominantly in the periportal and perisinusoidal space, while the total content of 
collagens and noncollagenous components increases up to tenfold (34). Thus, the 
perisinusoidal low-density ECM is transformed to a high-density matrix characterized by 
accumulation of bundles of collagen fibrils and an electron-dense basement membrane.   
In the advanced stages of liver fibrosis, Collagens I and II are concentrated in the ECM, to 
levels elevated 6-fold compared to normal states (6).  In our present study, Collagen II A1 
mRNA was upregulated 100-fold, while Collagens XII A1 and XIV A1 mRNAs, implicated 
in stabilizing collagen fibril structure during development and remodeling (24, 47), were up-
regulated 3.2 and 53 fold, respectively (Table III). The mRNA for lysyl oxidase (LOX), 
required for crosslinking of collagens (2, 41), was also upregulated, by 3.2 fold (Table I).  
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Thus, the effect of HCV on hepatoma cell ECM resembled that observed during liver 
fibrogenesis.  However, the results need to be confirmed in normal liver.  
Thrombospondins (THBS3 and THBS4) and chemokines (CXCL10 and CXCL6) were 
upregulated in Replicon cell line. IGFBP2 gene expression was also significantly 
upregulated (Table I). IGFBP2 expression is increased in HBV associated HCC (19). In this 
study, THBS1, TIMP1, TIMP2, TIMP4 were down regulated. Laminin is the main type of 
adhesive ECM and is associated with the formation of Basement membrane in liver during 
cirrhosis. Our study shows that LAMB3, LAMC1 and LAMC2 were increased in Replicon 
cell line (Table I).  
The topic of HCV and the cell surface is of high interest, from a receptor standpoint, since 
the mechanism of HCV infection is rather unique (26). Recent studies have indicated an 
alternative, claudin-mediated pathway of direct spread of HCV from cell to cell, without an 
extracellular viral stage (8). Of interest, claudin 6 was significantly upregulated (8.4 fold) 
(data not shown) in our study, but the significance towards HCV infection dynamics was 
not assessed.  
HCV involvement in hepatic fibrogenesis, through a direct effect on Hepatic Stellate Cells 
(HSCs), has previously been suggested (39).  In separate studies, HCV core isolated from 
hepatocellular carcinoma cells ex vivo was capable of shifting TGF-β responses from 
cytostatic effects, toward Epidermal Mesenchymal Transition (EMT), in primary mouse or 
human hepatocytes (4, 33).  The present study is the first to describe a potential fibrogenic 
effect of HCV on hepatocyte-derived hepatoma cells, and potential role of TGFbeta in this 
effect.  Natural variation in HCV core interaction with the TGFbeta pathway has been 
implicated in liver oncogenesis (4, 33).  In the present study, although TGFβ1 was down 
regulated in Replicon 1a cells, several other genes which interact with TGFβ were 
upregulated, such as FBN1 (Fibrillin 1) LOXL1, NDRG4, Collagen type XVI type, and 
several other transcription factors including HOXD1, HOXC10 and CAND2.  Since 
TGFbeta is a pluripotent master regulator of many processes, including injury repair, the 
overall effect of HCV on TGFbeta regulated mechanisms, and visa versa, needs to be 
determined. 
Induction of GFAP by NS5A, via a TGFbeta-independent mechanism, is a novel finding of 
the present study.  Modulation of cellular gene expression is a well-known function of 
NS5A (26), and NS5A has been reported to be a negative modulator of the TGF-beta1 signal 
transduction pathway (11); reduced phosphorylation and nuclear translocation of Smad2, as 
well as reduced heterodimerization of Smad3 with Smad4, were both observed in the 
presence of NS5A, and were apparently mediated via direct binding of NS5A to the TGF-
beta1 receptor, TbetaR1.  Whether or not the NS5A effect was mediated by a soluble factor 
was not assessed for the present study, and requires further investigation.  In the CNS, 
GFAP is induced by both TGFbeta dependent and independent mechanisms (27), and 
mediators of TGFbeta independent induction of GFAP have yet to be defined.   Determining 
the mechanism of GFAP induction by NS5A, and determining the overall significance to 
liver infection by HCV, are important goals of future research. 
The present results also raise a diagnostic question: the possibility that increases in GFAP 
positivity with advanced hepatitis C liver disease may in fact be due to HCV infection of 
hepatocytes.  Evidence for this in the present study included 1) co-localization of GFAP 
signal with either core or NS5A protein in hepatoma cell culture following gene 
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transfection (in addition to diffuse GFAP signal in cells neighboring core-expressing cells); 
2) high correlation between percentage of cells harboring GFAP and HCV replicative 
intermediate (RI) RNA in serial sections from liver biopsies of HCV-infected study 
subjects; and 3) high correlation between both markers and degree of hepatic fibrosis in 
the same liver biopsies. Other lines of human investigation have reveled highly significant 
associations between HCV genotype 1 infection virology in humans, and hepatitis C 
disease severity.  Both iatrogenic and viral induced immune suppression dramatically 
accelerates rates and incidence of hepatitis C progression (15, 40).  Longitudinal studies 
have identified genetic evidence of selective outgrowth of high fitness viral variants 
during disease progression (20, 21).  Finally, as alluded to above, intrahepatic HCV 
replication, as well as nonstructural antigen expression, have been highly correlated with 
hepatitis C liver disease severity, in the settings of liver transplantation (10, 16), natural 
infection, and HIV coinfection (31). 
These findings collectively support an intriguing hypothesis, that fibrogenesis in hepatitis C 
may in part be mediated by fibrogenic-like transitions of infected hepatocytes.  
In particular, the study draws attention to major cytoskeletal effects of HCV on hepatoma 
cells, and suggests that such effect may potentially represent a pro-fibrogenic response.  The 
study implicates two HCV proteins as potential mediators of the cytoskeletal changes:  HCV 
core and NS5A.  Questions as to the relevance and consequences of HCV modulation of the 
extracellular matrix remain to be addressed. The potential significance of the observed 
interaction to HCV life cycle, also needs further investigation. 
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disciplines.
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